Towards a world without cervical cancer
Detecting cervical cancer in its initial stages allows treatment to begin sooner and increases chances of survival - in some cases by nearly ninety-five percent. However, symptoms of the disease are not always evident early, making detection challenging.
Cervical cancer, which is the fourth most common cancer type in women globally, is caused by the Human Papilloma Virus (HPV), which is a common sexually transmitted infection (STI) seen in men and women. Most HPV infections present no symptoms and disappear naturally overtime. However, several genotypes like HPV16 and 18 have associated with cervical cancer development.
Regular examinations to monitor healthy individuals for cervical cancer are recommended every three to five years for women between the ages of 25 and 65. Women are invited to have a cervical sample taken by their GP or physician. While public screening programs have been implemented in several countries, participation remains low with a little as 60% (or even less) of women participating even after standard invitations and reminder calls.
Colli-Pee, an innovative medical device, enables first-void urine collection in a simple manner. Its unique design creates an easy way to capture the first 20 ml and permits superfluous urine to pass directly into the toilet. The initial flow contains higher concentrations of HPV DNA, emphasising the importance of using a tool like Colli-Pee to obtain accurate results.
These past few years, Novosanis has invested in gathering scientific data on the detection of HPV in first-void urine collected using our Colli-Pee device.
A first-void urine sample can easily be taken at home by women. HPV testing on first-void urine collected through Colli-Pee could significantly increase participation in cervical cancer screening programs.
This new approach could be game-changing in the way cervical cancer is diagnosed in the future.